Skip to main content

Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs

Objective

The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s.
The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease.
Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/clinical medicine/pneumology/asthma
  • /medical and health sciences/basic medicine/neurology/parkinson
  • /medical and health sciences/basic medicine/neurology/multiple sclerosis

Call for proposal

FP7-SME-2013
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

AMAKEM NV
Address
Agoralaan Gebouw Abis Bioville
3590 Diepenbeek
Belgium
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 320 235
Administrative Contact
Jack Veuskens (Dr.)

Participants (5)

COMPLIX NV
Belgium
EU contribution
€ 374 599
Address
Agoralaan Building A Bis Bioville
3590 Diepenbeek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thore Hettmann (Dr.)
FAST FORWARD PHARMACEUTICALS BV
Netherlands
EU contribution
€ 172 616
Address
Yalelaan 46
3584 CM Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mark De Boer (Mr.)
MIND-NRG SA
Switzerland
EU contribution
€ 354 550
Address
Rue De Jargonnant 2
1207 Geneve
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bertrand Damour (Mr.)
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Netherlands
EU contribution
€ 6 000
Address
Lange Kleiweg 161
2288 GJ Rijswijk Zh
Activity type
Research Organisations
Administrative Contact
Bert T Hart (Prof.)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 6 000
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Andrea Zeumann (Ms.)